ALISCA®-Lung2: A Phase 2 Study of Alisertib, an Investigational Drug, in Combination with Paclitaxel in Patients with Small Cell Lung Cancer



Clinical Trial Information Sheet

Alisertib is an investigational drug and it has not been approved by any health authority. Safety and efficacy of alisertib have not been established.

Puma Biotechnology is committed to patients and care partners having the information you need to make informed decisions with your healthcare provider about your treatment options.

ABOUT THIS CLINICAL TRIAL

The ALISCA-Lung2 is a Phase 2 clinical trial of alisertib administered in combination with paclitaxel in patients with small cell lung cancer (SCLC).

WHO IS ELIGIBLE?

The ALISCA-Lung2 clinical trial is open to patients 18 years or older with pathologically confirmed SCLC following progression on or after treatment with up to two prior treatment regimens. Patients must have received treatment with one platinum-based chemotherapy and immunotherapy. Talk to your doctor to discuss your eligibility.

WHAT'S INVOLVED?

- A screening period (to do some tests and procedures to confirm eligibility)
- A treatment period (total length depends on each patient)
- An end-of-treatment visit (when the patient stops taking alisertib)
- A safety follow-up visit (approximately 28 days after the last dose of alisertib)
- A long-term follow-up period
- Total length of participation in the clinical trial is approximately 11 months

WHO IS SPONSORING THIS CLINICAL TRIAL?

This trial is sponsored by Puma Biotechnology, a biopharmaceutical company focused on developing treatment options for different types of cancer.

The ALISCA-Lung2 alisertib trial is OPEN for enrollment!

For more information on the clinical trial, location of trial sites, and how to enroll,

- go to: https://clinicaltrials.gov/study/NCT07465757
- email: clinicaltrials@pumabiotechnology.com

For more information on the trial Sponsor,

- go to: www.pumabiotechnology.com

This sheet is a high-level snapshot of the trial. Please refer to the websites listed for more complete information.